Skip to main content
SpringerLink
Log in

Edoxaban Tosylate

  • Adis R&D Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Daiichi Sankyo Inc. U.S. Subsidiaries Join Together to Form Daiichi Sankyo, Inc. www.daiichisankyo-us.com, 03 Apr 2006.

  2. Daiichi Sankyo Company Limited. Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Hip Replacement. www.daiichisankyo.com, 08 Dec 2010.

  3. Daiichi Sankyo Company Limited. Edoxaban demonstrates superior efficacy compared with enoxaparin sodium in preventing vte after total knee replacement. www.daiichisankyo.com, 12 Jul 2010.

  4. Daiichi Sankyo Company Limited. Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban. www.daiichisankyo. com, 06 Apr 2010.

  5. Daiichi Sankyo Company Limited. Results of a Clinical Phase III Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism. www.daiichisankyo.com, 11 Dec 2009.

  6. A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial).

  7. A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial).

  8. Daiichi Sankyo Europe GmbH. DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF and for the Treatment of VTE is Proceeding as Planned. www.daiichisankyo.com, 01 Sep 2010.

  9. Daiichi Sankyo. HOKUSAI VTE — Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe. www.daiichi-sankyo.eu, 26 Feb 2010.

  10. Daiichi Sankyo Company Limited. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism. www.daiichi-sankyo.eu, 03 Feb 2010.

  11. Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

  12. A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial).

  13. Daiichi Sankyo. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b. www.daiichisankyo.com, 02 Sep 2008.

  14. A Phase IIa, Multi-Center, Multi-National, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty.

  15. Daiichi Sankyo. Edoxaban — Next Generation Oral Anticoagulant Under Investigation to Help Prevent Stroke in Patients With Atrial Fibrillation. www.daiichi-sankyo.eu, 01 Sep 2009.

  16. Daiichi Sankyo Europe GmbH. Edoxaban — Factor Xa Inhibitor Enters Phase III With Optimal Dose. www.daiichi-sankyo.eu, 27 Mar 2009.

  17. Daiichi Sankyo Co. Ltd. DAIICHI SANKYO Initiates Phase III Trial of its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation. www.daiichi-sankyo.eu, 07 Dec 2008.

  18. Daiichi Sankyo Company Limited. Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation. www.daiichisankyo.com, 01 Dec 2010.

  19. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects With Atrial Fibrillation — Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE — AF TIMI — 48).

  20. Daiichi Sankyo Company Limited. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation. www.daiichisankyo.com, 07 Dec 2008.

  21. A phase 2, randomized, parallel group, multicenter, multinational study for the evaluation of safety of four fixed dose regimens of DU 176b in subjects with non-valvular atrial fibrillation.

  22. Samama MM, Wolzt M, Ogata K, et al. Effect of edoxaban (DU-176b) on thrombin generation and platelet activation in shed and venous blood with fondaparinux as active comparator ESC Congress 2009: Annual Congress of the European Society of Cardiology: abstr. P2105, 29 Aug 2009. Available from URL: http: //www.escardio.org.

  23. Daiichi Sankyo. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing. www.daiichisankyo. com, 15 Jul 2009.

  24. Zafar MU, Gaztanaga J, Velez M, et al. A phase I study to assess the antithrombotic properties of DU-176b: an orally active direct factor-Xa inhibitor. Journal of the American College of Cardiology. 47 (Suppl. A): 288, No. 4, 21 Feb 2006.

    Google Scholar 

  25. Koretsune Y, Inoue H, Kawai Y, et al. The oral factor Xa inhibitor DU-176b in Japanese warfarin-naive patients with atrial fibrillation: results of two phase II open-label, dose-escalation studies. 58th Annual Scientific Session of the American College of Cardiology: 430–431 abstr. 1022–114, 10 Mar 2009. Available from URL: http: //www.sciencedirect.com.

  26. Morishima Y, Furugohri T, Isobe K, et al. In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b. Blood. 104: 515 (plus poster) abstr. 1862, No. 11, Part 1, 16 Nov 2004.

  27. Fukuda T, Matsumoto C, Honda Y, et al. Antithrombotic properties of DU-176b, a novel, potent and orally active direct factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor. Blood. 104: 513 (plus poster) abstr. 1852, No. 11, Part 1, 16 Nov 2004.

  28. Furugohri T, Honda Y, Matsumoto C, et al. Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct factor Xa inhibitor: a wider safety margin compared to heparins and warfarin. Blood. 104: 512 (plus poster) abstr. 1851, No. 11, Part 1, 16 Nov 2004.

  29. Raskob G, Cohen A, Eriksson B, et al. Randomized double-blind multi-dose trial of the oral factor-Xa inhibitor DU-176b versus LMW heparin (Dalteparin) for prevention of venous thromboembolism after total hip replacement. ESC Congress 2008: Annual Congress of the European Society of Cardiology: abstr. P3712, 30 Aug 2008. Available from URL: http: //www.escardio.org.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edoxaban Tosylate. Am J Cardiovasc Drugs 11, 129–135 (2011). https://doi.org/10.2165/11533660-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533660-000000000-00000

Search

Navigation